-
-
-
-
-
-
-
Lexeo finalizes pivotal trial design for gene therapy in heart condition
-
-
-
-
-
-
-
Oppenheimer on Lexeo Therapeutics (LXEO): 'We regard the selloff as having made the shares more attractive'
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Lexeo Therapeutics (LXEO) at Overweight
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) PT Lowered to $9 at H.C. Wainwright
-
-
-
-
-
-
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) Announces Positive Interim Phase 1/2 Data for LX2006
-
-
-
-
-
-
-
Lexeo Therapeutics, Inc. (LXEO) Misses Q3 EPS by 17c
-
466,880 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

